TJU Alumni Forum 首页 TJU Alumni Forum
 常见问题与解答 (FAQ)常见问题与解答 (FAQ)   搜索搜索   成员列表成员列表   成员组成员组   注册注册 
 个人资料个人资料   登陆查看您的私人留言登陆查看您的私人留言   登陆登陆 

Mitoriboscins: Mitochondrial-based therapeutics

发表新帖   回复帖子    TJU Alumni Forum 首页 -> 学术研究
阅读上一个主题 :: 阅读下一个主题  
作者 留言

注册时间: 2017-07-17
帖子: 2

帖子发表于: 星期一 七月 17, 2017 4:51 pm    发表主题: Mitoriboscins: Mitochondrial-based therapeutics 引用并回复

Oncotarget. 2017 Jul 7. doi: 10.18632/oncotarget.19084. [Epub ahead of print]
Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast.
Ozsvari B1,2, Fiorillo M1,2,3, Bonuccelli G1,2, Cappello AR3, Frattaruolo L3, Sotgia F1,2, Trowbridge R4, Foster R5,4, Lisanti MP1,2.
Author information
The "endo-symbiotic theory of mitochondrial evolution" states that mitochondrial organelles evolved from engulfed aerobic bacteria, after millions of years of symbiosis and adaptation. Here, we have exploited this premise to design new antibiotics and novel anti-cancer therapies, using a convergent approach. First, virtual high-throughput screening (vHTS) and computational chemistry were used to identify novel compounds binding to the 3D structure of the mammalian mitochondrial ribosome. The resulting library of ~880 compounds was then subjected to phenotypic drug screening on human cancer cells, to identify which compounds functionally induce ATP-depletion, which is characteristic of mitochondrial inhibition. Notably, the top ten "hit" compounds define four new classes of mitochondrial inhibitors. Next, we further validated that these novel mitochondrial inhibitors metabolically target mitochondrial respiration in cancer cells and effectively inhibit the propagation of cancer stem-like cells in vitro. Finally, we show that these mitochondrial inhibitors possess broad-spectrum antibiotic activity, preventing the growth of both gram-positive and gram-negative bacteria, as well as C. albicans - a pathogenic yeast. Remarkably, these novel antibiotics also were effective against methicillin-resistant Staphylococcus aureus (MRSA). Thus, this simple, yet systematic, approach to the discovery of mitochondrial ribosome inhibitors could provide a plethora of anti-microbials and anti-cancer therapies, to target drug-resistance that is characteristic of both i) tumor recurrence and ii) infectious disease. In summary, we have successfully used vHTS combined with phenotypic drug screening of human cancer cells to identify several new classes of broad-spectrum antibiotics that target both bacteria and pathogenic yeast. We propose the new term "mitoriboscins" to describe these novel mitochondrial-related antibiotics. Thus far, we have identified four different classes of mitoriboscins, such as: 1) mitoribocyclines, 2) mitoribomycins, 3) mitoribosporins and 4) mitoribofloxins. However, we broadly define mitoriboscins as any small molecule(s) or peptide(s) that bind to the mitoribosome (large or small subunits) and, as a consequence, inhibit mitochondrial function, i.e., mitoribosome inhibitors.
antibiotic; drug design; mitochondria; mitochondrial ribosome; mitoribosome
PMID: 28696944 DOI: 10.18632/oncotarget.19084
Free full text
阅览成员资料 (Profile) 发送私人留言 (PM)
发表新帖   回复帖子    TJU Alumni Forum 首页 -> 学术研究 论坛时间为 GMT


Powered by phpBB © phpBB Group. Hosted by

Free Web Hosting | File Hosting | Photo Gallery | Matrimonial

Powered by, setup your forum now!
For Support, visit